Brainstorm Cell Therapeutics (BCLI) Competitors $1.27 +0.01 (+0.79%) (As of 10:09 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BCLI vs. KALA, DARE, PLUR, DRRX, NAII, INKT, LGVN, MRKR, LPCN, and ATHAShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include KALA BIO (KALA), Daré Bioscience (DARE), Pluri (PLUR), DURECT (DRRX), Natural Alternatives International (NAII), MiNK Therapeutics (INKT), Longeveron (LGVN), Marker Therapeutics (MRKR), Lipocine (LPCN), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. KALA BIO Daré Bioscience Pluri DURECT Natural Alternatives International MiNK Therapeutics Longeveron Marker Therapeutics Lipocine Athira Pharma KALA BIO (NASDAQ:KALA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Do analysts rate KALA or BCLI? KALA BIO presently has a consensus target price of $15.00, indicating a potential upside of 144.30%. Brainstorm Cell Therapeutics has a consensus target price of $30.00, indicating a potential upside of 2,300.00%. Given Brainstorm Cell Therapeutics' higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KALA or BCLI more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -448.61% -69.37% Brainstorm Cell Therapeutics N/A N/A -528.56% Do institutionals and insiders believe in KALA or BCLI? 24.6% of KALA BIO shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 8.3% of KALA BIO shares are held by insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in KALA or BCLI? KALA BIO received 9 more outperform votes than Brainstorm Cell Therapeutics when rated by MarketBeat users. Likewise, 66.82% of users gave KALA BIO an outperform vote while only 61.26% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformKALA BIOOutperform Votes30066.82% Underperform Votes14933.18% Brainstorm Cell TherapeuticsOutperform Votes29161.26% Underperform Votes18438.74% Which has better earnings and valuation, KALA or BCLI? Brainstorm Cell Therapeutics has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M7.28-$42.20M-$12.47-0.49Brainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.26 Does the media prefer KALA or BCLI? In the previous week, KALA BIO had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 4 mentions for KALA BIO and 3 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 1.00 beat KALA BIO's score of 0.20 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, KALA or BCLI? KALA BIO has a beta of -2.13, suggesting that its stock price is 313% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. SummaryKALA BIO beats Brainstorm Cell Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.13M$2.95B$5.07B$8.80BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.2616.8789.5613.60Price / SalesN/A280.301,224.8087.40Price / CashN/A169.3839.4536.27Price / Book-1.184.436.976.33Net Income-$17.19M-$41.63M$119.04M$225.93M7 Day Performance10.62%-5.15%-1.78%-0.96%1 Month Performance-42.92%-6.91%-3.59%1.06%1 Year Performance-62.09%25.64%31.64%26.59% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics4.4456 of 5 stars$1.25-0.8%$30.00+2,300.0%-53.4%$7.13MN/A-0.2640Analyst UpgradePositive NewsKALAKALA BIO4.0824 of 5 stars$6.14-4.5%$15.00+144.3%+7.8%$28.31M$3.89M0.0030INKTMiNK Therapeutics3.2235 of 5 stars$0.71+0.7%$6.50+815.5%-34.1%$28.08MN/A-1.8130Analyst RevisionDAREDaré Bioscience2.203 of 5 stars$3.21+0.9%$24.00+647.7%-23.9%$27.93M$2.81M-5.3830PLURPluri0.1524 of 5 stars$4.99-1.4%N/A+11.5%$27.74M$330,000.000.00150NAIINatural Alternatives International0.3468 of 5 stars$4.36-1.4%N/A-27.8%$27.03M$113.80M0.00290Analyst ForecastNews CoverageDRRXDURECT3.0843 of 5 stars$0.86-4.7%$5.00+480.7%+39.5%$26.73M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageMRKRMarker Therapeutics3.8639 of 5 stars$2.96-6.9%$19.00+541.9%+17.8%$26.40M$3.31M0.0060LGVNLongeveron2.3938 of 5 stars$1.81-2.2%$8.00+342.0%-90.4%$25.99M$710,000.000.0023LPCNLipocine2.0423 of 5 stars$4.83+2.5%$10.00+107.0%+96.3%$25.84M$500,000.00-6.7110EQEquillium3.1992 of 5 stars$0.70-2.1%$5.00+611.4%+43.6%$24.90M$36.08M0.0040Analyst Revision Related Companies and Tools Related Companies KALA Competitors DARE Competitors PLUR Competitors DRRX Competitors NAII Competitors INKT Competitors LGVN Competitors MRKR Competitors LPCN Competitors ATHA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCLI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts